Dogwood secures royalty free license to develop, commercialize SP16

Dogwood (DWTX) Therapeutics announced that in an all-stock transaction, it has secured a royalty free, global license to develop Serpin Pharma’s intravenous formulation of SP16 to manage cancer related pain including a broad range of chemotherapy induced neuropathy symptoms. Serpin Pharma has discovered the active portion of A1AT responsible for both the anti-inflammatory activity as well as tissue repair, and this active portion is represented by SP16. SP16 is a first-in-class LRP1 agonist which has demonstrated both anti-inflammatory and neural repair activity that has the potential to treat chemotherapy-induced peripheral neuropathy. SP16 IV is the focus of a forthcoming Phase 1b CIPN study that is fully funded by the National Cancer Institute, reflecting the uniqueness of this approach, as well as the extraordinary unmet medical need associated with this debilitating cancer-related condition. SP16 IV mimics the activity of alpha-1-antitrypsin’s anti-inflammatory and immunomodulatory actions. In preclinical research, SP16 has demonstrated anti-inflammatory and analgesic benefits, as well as neural restorative and repair activity, both of which hold promise for addressing the multitude of symptoms and damage and functional complication of CIPN. Halneuron is a NaV1.7 specific sodium channel inhibitor that has demonstrated statistically significant and clinically meaningful pain reductions in general cancer pain, as well as chemotherapy induced neuropathic pain, respectively. Halneuron is currently in Phase 2b development to treat CINP, a condition for which the medicine has been granted fast-track review designation by the FDA. Over eighty patients have been recruited to date in this landmark Phase 2b CINP study, with interim data from 90-100 patients projected in December 2025. Pursuant to an exclusive licensing agreement Serpin Pharma, Inc. and its designated affiliates will receive 382,034 shares of DWTX common stock and 179.1878 shares of a new series of non-voting convertible preferred stock which collectively represents 7.31% of the Company’s common stock, on a fully diluted basis which assumes conversion of all series of outstanding preferred stock of the Company including any transaction fees. The issuance of shares of common stock upon conversion of the Preferred Stock shall be subject to stockholder approval in compliance with the rules of the Nasdaq Stock Market.